The response pattern of patients with chronic airway obstruction to bronchodilators.

S C Yang, M C Wu
{"title":"The response pattern of patients with chronic airway obstruction to bronchodilators.","authors":"S C Yang,&nbsp;M C Wu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>To investigate the response pattern of patients with chronic airway obstruction (CAO) to bronchodilators, 128 subjects consisting of 80 men and 48 women with a mean age of 52.6 years were randomly tested with three inhalant bronchodilators: a non-selective beta-agonist (isoproterenol), a beta 2-selective agonist (terbutaline) and an anticholinergics (ipratropium) plus placebo. All patients had a baseline FEV/FVC of less than 65% and their clinical diagnosis were classified as either COPD or bronchial asthma according to the criteria of the ACCP-ATS Joint Committee on Pulmonary Nomenclature. The drugs were delivered to the patient via a metered dose inhaler (MDI) using the conventional inhalation technique. Spirometry was measured at regular intervals with a computerized pulmonary function analyzer CHESTAC-65(Japan). A more than 15% increase in FEV1 and/or FVC after treatment was regarded as responsive. While 108 patients were tested with a single drug, the remaining 20 patients were tested sequentially with terbutaline, ipratropium and placebo in a randomized cross-over manner for studying additivity. Our results showed that the response rates of asthmatic patients to isoproterenol, terbutaline and ipratropium were 50%, 87% and 67%, respectively. Only 27% of COPD patients responded to isoproterenol and 60% to terbutaline. On the other hand, ipratropium possessed a 61% response rate in the treatment of COPD and showed a bronchodilator effect independent to that of terbutaline. Combined use of both drugs resulted in additional improvement. Once patients responded to the drugs, apparent changes in FEV1 and/or FVC occurred within 30 minutes and reached the maximum usually at 60 minutes post-inhalation.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":22189,"journal":{"name":"Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1989-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

To investigate the response pattern of patients with chronic airway obstruction (CAO) to bronchodilators, 128 subjects consisting of 80 men and 48 women with a mean age of 52.6 years were randomly tested with three inhalant bronchodilators: a non-selective beta-agonist (isoproterenol), a beta 2-selective agonist (terbutaline) and an anticholinergics (ipratropium) plus placebo. All patients had a baseline FEV/FVC of less than 65% and their clinical diagnosis were classified as either COPD or bronchial asthma according to the criteria of the ACCP-ATS Joint Committee on Pulmonary Nomenclature. The drugs were delivered to the patient via a metered dose inhaler (MDI) using the conventional inhalation technique. Spirometry was measured at regular intervals with a computerized pulmonary function analyzer CHESTAC-65(Japan). A more than 15% increase in FEV1 and/or FVC after treatment was regarded as responsive. While 108 patients were tested with a single drug, the remaining 20 patients were tested sequentially with terbutaline, ipratropium and placebo in a randomized cross-over manner for studying additivity. Our results showed that the response rates of asthmatic patients to isoproterenol, terbutaline and ipratropium were 50%, 87% and 67%, respectively. Only 27% of COPD patients responded to isoproterenol and 60% to terbutaline. On the other hand, ipratropium possessed a 61% response rate in the treatment of COPD and showed a bronchodilator effect independent to that of terbutaline. Combined use of both drugs resulted in additional improvement. Once patients responded to the drugs, apparent changes in FEV1 and/or FVC occurred within 30 minutes and reached the maximum usually at 60 minutes post-inhalation.(ABSTRACT TRUNCATED AT 250 WORDS)

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性气道阻塞患者对支气管扩张剂的反应模式。
为了研究慢性气道阻塞(CAO)患者对支气管扩张剂的反应模式,128名受试者,包括80名男性和48名女性,平均年龄52.6岁,随机接受三种吸入性支气管扩张剂的试验:非选择性β -受体激动剂(异丙肾上腺素),β - 2选择性受体激动剂(特布他林)和抗胆碱能剂(异丙托品)加安慰剂。所有患者的基线FEV/FVC均小于65%,根据ACCP-ATS肺命名联合委员会的标准,他们的临床诊断被分类为COPD或支气管哮喘。药物通过常规吸入技术的计量吸入器(MDI)输送给患者。用计算机化肺功能分析仪CHESTAC-65(日本)定期测量肺活量。治疗后FEV1和/或FVC增加15%以上被认为是反应性的。108例患者使用单一药物进行测试,其余20例患者以随机交叉的方式依次使用特布他林、异丙托品和安慰剂进行测试,以研究可加性。结果显示,哮喘患者对异丙肾上腺素、特布他林和异丙托品的有效率分别为50%、87%和67%。只有27%的COPD患者对异丙肾上腺素有反应,60%的患者对特布他林有反应。另一方面,异丙托品治疗COPD的有效率为61%,其支气管扩张作用独立于特布他林。两种药物联合使用可进一步改善病情。一旦患者对药物有反应,FEV1和/或FVC在30分钟内发生明显变化,通常在吸入后60分钟达到最大值。(摘要删节250字)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Rapid spectrophotometric method for quantitation of acetaminophen in serum. Apolipoproteins A-I and B in non-insulin-dependent diabetes mellitus. Postoperative echocardiographic study of patients with symptomatic chronic aortic regurgitation. Cytomegalovirus retinitis treated with ganciclovir in a renal transplant recipient. Anterior pituitary functions in patients with uremia tested by stimulation with four combined hypothalamic releasing hormones.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1